Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well selumetinib works in treating patients with
recurrent or persistent endometrial cancer that has come back or is persistent. Selumetinib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.